Table 1.
VACS 8 cohort (n=7324) characteristics at baseline (unless otherwise specified), by HIV status
| HIV+ (n=3683) | Uninfected (n=3641) | p-value | |
|---|---|---|---|
| DEMOGRAPHICS | |||
| Age in years, mean (SD) | 49.3 (8.9) | 50.5 (9.9) | <0.0001 |
| Male gender, % | 97.6 | 92.5 | <0.0001 |
| Race, % | <0.0001 | ||
| Black | 70.0 | 63.0 | |
| White | 28.1 | 30.4 | |
| Other | 2.0 | 6.6 | |
| Body mass index (BMI), kg/m2, median (IQR) | 25.1 (22.6, 28.1) | 28.8 (25.5, 32.7) | <0.0001 |
| BMI <25 kg/m2, % | 49.3 | 21.9 | <0.0001 |
| BMI 25-35 kg/m2, % | 48.2 | 64.9 | |
| BMI >35 kg/m2, % | 2.5 | 13.2 | |
| CD4, median cells/ml (IQR) | 366 (210, 553) | n/a | |
| CD4 <200 cells/ml, % | 23.2 | n/a | |
| HIV RNA, median copies/ml (IQR) | 448 (75, 15452) | n/a | |
| HIV RNA <400 copies/ml, % | 40.8 | n/a | |
| Combination antiretroviral therapy use, % | 72.7 | n/a | |
| Smoking status, % | <0.0001 | ||
| Current | 53.6 | 45.7 | |
| Former | 23.9 | 26.9 | |
| Never | 22.5 | 27.5 | |
| Hazardous alcohol use, % | 44.3 | 48.1 | 0.001 |
| COMORBIDITIES | |||
| Cardiovascular disease, % | 2.6 | 4.1 | 0.0004 |
| Hypertension, % | 25.9 | 46.9 | <0.0001 |
| Diabetes, % | 25.3 | 33.4 | <0.0001 |
| Chronic obstructive pulmonary disease, % | 4.3 | 5.1 | 0.2 |
| Major depression, % | 11.2 | 12.4 | 0.1 |
| Hepatitis C, % | 26.9 | 14.5 | <0.0001 |
| Hepatitis B, % | 4.5 | 1.2 | <0.0001 |
|
OSA DIAGNOSIS, TESTING, TREATMENT, AND
SELF-REPORT |
|||
| OSA ICD-9 code at baseline, % | 0.8 | 3.1 | <0.0001 |
| OSA ICD-9 code at any time, % | 3.9 | 12.4 | <0.0001 |
| Polysomnogram, %* | 2.8 | 7.8 | <0.0001 |
| Home sleep test, %* | 0.2 | 1.4 | <0.0001 |
| CPAP CPT code, %* | 2.3 | 6.4 | <0.0001 |
| Self-reported sleep apnea during follow-up, %** | 8.2 | 14.6 | <0.0001 |
| OSA by ICD-9 (any time) or CPAP CPT or self report, % |
10.0 | 20.1 | <0.0001 |
| OSA-RELATED SYMPTOMS | |||
| Tired/fatigue, % | 51.9 | 44.6 | <0.0001 |
| Concentration difficulty, % | 31.8 | 31.6 | 0.4 |
*
data include events at baseline or during follow-up
**
includes follow-up survey data from 2488/3683 (68%) HIV+ and 2455/3641 (67%) uninfected VACS 8 participants; p=0.9 between HIV+ and uninfected follow-up survey completion rate.